|
HLTF expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.50832687953562E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.68759492228332E-11 |
| Normal-vs-Stage2 |
5.151000E-04 |
| Normal-vs-Stage3 |
1.55659929390595E-11 |
| Normal-vs-Stage4 |
8.62643290133747E-14 |
| Stage1-vs-Stage2 |
1.249650E-01 |
| Stage1-vs-Stage3 |
1.360350E-01 |
| Stage1-vs-Stage4 |
4.374300E-04 |
| Stage2-vs-Stage3 |
1.957830E-02 |
| Stage2-vs-Stage4 |
5.987500E-04 |
| Stage3-vs-Stage4 |
6.385600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.44009282066327E-15 |
| Normal-vs-AfricanAmerican |
1.194110E-02 |
| Normal-vs-Asian |
6.69910016348751E-10 |
| Caucasian-vs-AfricanAmerican |
1.424130E-02 |
| Caucasian-vs-Asian |
9.644800E-01 |
| AfricanAmerican-vs-Asian |
5.158400E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.50940038246006E-10 |
| Normal-vs-Female |
6.87438994617651E-12 |
| Male-vs-Female |
4.121200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.36189964755818E-11 |
| Normal-vs-Age(41-60Yrs) |
1.43750011893928E-10 |
| Normal-vs-Age(61-80Yrs) |
1.07490000234023E-08 |
| Normal-vs-Age(81-100Yrs) |
1.188450E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.119200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.302800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.189200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.777000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.061000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.626000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.003900E-04 |
| Classical-VS-Follicular |
4.542800E-03 |
| Classical-VS-Other |
2.964000E-01 |
| Classical-VS-Normal |
1.96376248595698E-12 |
| Tall-VS-Follicular |
6.32869999961372E-07 |
| Tall-VS-Other |
6.486600E-01 |
| Tall-VS-Normal |
1.9773072068574E-13 |
| Follicular-VS-Other |
8.781500E-02 |
| Follicular-VS-Normal |
1.102440E-03 |
| Other-VS-Normal |
3.756300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.0066000033504E-08 |
| Normal-vs-N1 |
2.08721928629529E-14 |
| N0-vs-N1 |
6.32109999999519E-05 |
|
|
